JAZZ - Jazz Pharmaceuticals Corp Total Debt to Capital

Jazz Pharmaceuticals (JAZZ) relies on manufacturing capacities in the US and Ireland, dominating the fields of oncology therapy and sleep disorders. Its intellectual potential is driven by a staff of leading neurobiologists and rare disease specialists. However, generics and government price controls threaten profits. This chart of the stock price relative to the total debt-to-equity ratio reflects 0.89.

To assess the resilience of Jazz Pharmaceuticals (JAZZ), it is critical to analyze the business's degree of dependence on borrowed funds. The financial leverage ratio (total debt-to-equity) compares total liabilities to equity to determine default risk; for the biopharmaceutical sector with inelastic demand for drugs, a moderate debt load on the chart confirms the company's ability to scale effectively without threatening its financial stability.